



## Genetic and mechanistic studies in NAFLD to identify therapeutic targets

## Yaron Rotman, MD, MSc

Clinical Investigator and Acting Chief of Liver and Energy Metabolism Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD

## Tuesday, June 15, 2021 5:00 - 6:00 pm

https://zoom.us/j/99179243625?pwd=TTFKQ2pmeUsvSUdFOExLdHJMM0dYdz09

Host: Silvia Vilarinho, MD, PhD

To record your attendance to this activity, text the Activity Code (**20561**) for your RSS activity to **203-442-9435**. You will receive a message back that verifies your activity attendance has been recorded for CME credit.

There is no corporate support for this activity. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Target Audience: YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity. Needs assessment: NAFLD is a common disease with no approved treatment. Better understanding of disease mechanisms is essential to developing therapeutic interventions. The genetic determinants of disease are an excellent tool to identify therapeutic targets. Objectives: Describe how genetic variability can lead to identification of therapeutic targets; Discuss the strengths of limitations of animal models in studies of NAFLD; Review upcoming therapies based on genetic studies. Faculty Disclosures: Y Rotman – Gilead Sciences; S Vilarinho – None. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. This course will fulfill the licensure requirement set forth by the State of Connecticut.